UNITED STATES

SECURITIES AND EXCHANGE COMMISSION


Washington, DC 20549

 




FORM 8-K


CURRENT REPORT


PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 





Date of Report (Date of earliest event reported):   April 29, 2008

 

 

 

ANGIOTECH PHARMACEUTICALS, INC.

(Exact name of registrant as specified in charter)

                                                                                                                        

 

BRITISH COLUMBIA

000-30334

98-0226269

 (State or other jurisdiction of incorporation)

(Commission file number)

(IRS employer identification no.)

 

 

1618 Station Street, Vancouver, BC, Canada

V6A 1B6

(Address of principal executive offices)

(Zip code)

 

 

Registrant’s telephone number, including area code:  (604) 221-7676


 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the fling obligation of the registrant under any of the following provisions:


o    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







 


ITEM 2.02












RESULTS OF OPERATIONS AND FINANCIAL CONDITION


On April 29, 2008, Angiotech Pharmaceuticals, Inc. issued a press release relating to its results of operations and financial condition for the quarter ended March 31, 2008.  The full text of Angiotech's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.





ITEM 9.01


(d)


99.1

FINANCIAL STATEMENTS AND EXHIBITS


Exhibits


Press release of Angiotech Pharmaceuticals, Inc. dated April 29, 2008.







 

SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ANGIOTECH PHARMACEUTICALS, INC.

 

 

 

 

 

Date:   April 29, 2008

By:

/s/ K. Thomas Bailey 

 

 

Name:  K. Thomas Bailey 

 

 

Title:  Chief Financial Officer 

 

 

 





EXHIBIT INDEX


 EXHIBIT

DESCRIPTION

 99.1

Press Release of Angiotech Pharmaceuticals, Inc. dated April 29, 2008.





Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Angiotech Pharmaceuticals - Common Shares (MM) Charts.
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Angiotech Pharmaceuticals - Common Shares (MM) Charts.